FAMVIR
LOE ApproachingNDAORALTABLET
Approved
Jun 1994
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 4h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FAMVIR is an oral small-molecule antiviral drug approved by Novartis in 1994. The product is formulated as a tablet for systemic treatment of viral infections. Specific indications and mechanism of action data are not available in the current dataset.
LOE Approaching
Approaching loss of exclusivity with moderate competitive pressure (30% metric) suggests team is in defensive/transition planning mode with likely downsizing or redeployment of commercial resources.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on FAMVIR offers limited long-term career growth due to approaching loss of exclusivity and minimal job openings (0 linked positions). Professionals should expect portfolio transition strategies and potential team restructuring as the product moves toward post-LOE management.
Brand ManagerField Sales Representative
Worked on FAMVIR at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.